CXCR7 (2019)

Thanigaimalai Pillaiyar1,2, Stefan Laufer1,2,3

  • 1Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Eberhard Karls University Tübingen, Tübingen, Germany.

概括

非典型的化学因受体3 (ACKR3) 调节剂在治疗癌症和疼痛等疾病方面表现有前途. 最近的专利强调了心血管/疼痛疾病的激动剂和癌症和自身免疫性疾病的对抗剂.